On Friday, Shares of NetApp, Inc. (NASDAQ:NTAP), gained 4.31% to $33.14.
NetApp, declared that Tim Russell, VP, Product Administration, will take part in a fireside chat at the D. A. Davidson Conference at 11:30 a.m. Eastern Time on May 27, 2015.
NetApp, Inc. is engaged in design, manufacture, and marketing of networked storage solutions. The company provides storage and data administration software, systems, and services. It offers Data ONTAP storage operating system that delivers integrated data protection, comprehensive data administration, and built-in efficiency software for virtualized, shared infrastructures, cloud computing, and mixed workload business applications; storage efficiency technologies.
Finally, Sarepta Therapeutics, Inc. (NASDAQ:SRPT), ended its last trade with 8.08% gain, and closed at $26.22.
On May 12, Sarepta Therapeutics, declared equity awards granted on May 11, 2015, that were formerly approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to the employment of two individuals hired by Sarepta in May 2015. The equity awards were approved in accordance with NASDAQ Listing Rule 5635(c)(4).
The employees received, in the aggregate, options to purchase 117,000 shares of Sarepta’s common stock. The options have an exercise price of $15.04 per share, which is equal to the closing price of Sarepta’s common stock on May 11, 2015. One-fourth of the shares underlying each employee’s option will vest on the one year anniversary of his or her date of hire and thereafter 1/48th of the shares underlying each employee’s option will vest monthly, such that the shares underlying the option granted to each employee will be fully vested on the fourth anniversary of his or her date of hire, in each case, subject to each such employee’s continued employment with Sarepta on such vesting dates.
Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases. Its lead product candidate is Eteplirsen, an antisense phosphorodiamidate morpholino oligomer therapeutic, which is in Phase III clinical development stage for the treatment of individuals with Duchenne muscular dystrophy (DMD), a rare genetic muscle-wasting disease caused by the absence of dystrophin.